CORRESP Filing
HERON THERAPEUTICS, INC. /DE/
Date: Sept. 12, 2025 · CIK: 0000818033 · Accession: 0000950170-25-114548
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-290142
Letter
Attention: Tim Buchmiller Registration Statement on Form S-3 File No. 333-290142 Filed September 9, 2025
Re: Heron Therapeutics, Inc.
Dear Mr. Buchmiller: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Heron Therapeutics, Inc. (the “ Compan y”) hereby requests acceleration of the effective date of the above referenced Registration Statement to 4:00 p.m., Eastern Time, on September 16, 2025, or as soon thereafter as practicable, or at such other time as the Company or its outside counsel, DLA Piper LLP (US), request by telephone that such Registration Statement be declared effective. Please contact Andrew P. Gilbert, of DLA Piper LLP (US), counsel to the Company, at (973) 520-2553, as soon as the registration statement has been declared effective, or if you have any other questions or concerns regarding this matter.
Sincerely,
HERON THERAPEUTICS, INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP Heron Therapeutics, Inc. 100 Regency Forest Drive, Suite 300 Cary, North Carolina 27518 September 12, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Tim Buchmiller Re: Heron Therapeutics, Inc. Registration Statement on Form S-3 File No. 333-290142 Filed September 9, 2025 Dear Mr. Buchmiller: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Heron Therapeutics, Inc. (the “ Compan y”) hereby requests acceleration of the effective date of the above referenced Registration Statement to 4:00 p.m., Eastern Time, on September 16, 2025, or as soon thereafter as practicable, or at such other time as the Company or its outside counsel, DLA Piper LLP (US), request by telephone that such Registration Statement be declared effective. Please contact Andrew P. Gilbert, of DLA Piper LLP (US), counsel to the Company, at (973) 520-2553, as soon as the registration statement has been declared effective, or if you have any other questions or concerns regarding this matter. Sincerely, HERON THERAPEUTICS, INC. By: /s/ Ira Duarte Name: Ira Duarte Title: Executive Vice President, Chief Financial Officer